were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), ST, and stroke.
Conclusions: Our results suggest that in patients undergoing percutaneous coronary intervention with stent implantation, smoking is not associated with ISR and MACE; however, smoking is an independent risk factor for MACCE
7] The Arterial Revascularization Therapy Study II trial has demonstrated that CABG therapy reduced the incidence of repeat revascularization and overall MACCE
, but it did not influence the hard end points, such as death and MI, compared to treatment with SES.
The trial results were also analyzed based on the SYNTAX Score, which demonstrated no statistically significant difference in MACCE
for patients in the lower two terciles - those with low lesion complexity (19.
Stepwise multivariate logistic regressions were used to analyze the predictors of MACCE
The gender analysis, a secondary-endpoint evaluation in the real-world CoreValve ADVANCE Study, found that survival rates were nearly identical between genders, with no statistical differences in 30-day and 6-month all-cause mortality, cardiovascular mortality or the 30-day MACCE
endpoint (Major Adverse Cardiac & Cerebrovascular Events, a composite of all-cause mortality, myocardial infarction, emergent cardiac surgery or percutaneous re-intervention, and stroke).
No significant difference was observed in the rate of MACCE
9 percent and MACCE
(Major Adverse Cardiac & Cerebrovascular Events) rates of 8.
At 5-year follow-up, the rates of all-cause death, cardiac death, MI, stroke, any repeat revascularization, and MACCE
in the overall cohort were 4.
After 12 months, subjects who are free from all MACCE
or major bleeding events will be randomized 1:1 to either placebo or ongoing dual antiplatelet therapy for an additional 18 months followed by three months of observational follow-up.
Our most recent analysis, presented today at SCAI, shows a significant reduction in MACCE
in favor of Impella.
The study protocol was for low ejection fraction (EF) patients with unprotected left main (EF 35%) or with triple vessel disease (EF 30%), measuring a primary endpoint of 10 major adverse event (MAE) components including MACCE
at 30 days for a total of 654 patients.